MAP2K7 and melanoma: The MEK inhibitors trametinib and cobimetinib have demonstrated clinical efficacy, particularly in combination with BRAF inhibitors, for the treatment of BRAF-mutant melanoma.287 These combinations have been approved for use based on their ability to improve outcomes, including progression-free survival and overall survival, in these patients.